- Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease
- Effectiveness and safety of rivaroxaban vs warfarin in frail patients with venous thromboembolism
- Allopurinol dose escalation and mortality among patients with gout: A national propensity-matched cohort study
- Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients
- Neither creatinine- nor cystatin C-estimated glomerular filtration rate is optimal in oncology patients treated with targeted agents
- Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: The TANGO I randomized clinical trial
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial
- Efficiency and predictive parameters of outcome of a multimodal pain management concept with spinal injections in patients with low back pain: A retrospective study of 445 patients
- Improved endothelial function after short-term therapy with evolocumab
- Fluoroquinolone use and risk of aortic aneurysm and dissection: Nationwide cohort study
- Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C-infected persons: Results from erchives
- Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands
- Psychotropic medications in older people in residential care facilities and associations with quality of life: A cross-sectional study
- Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016
- Changes in metformin use and other antihyperglycemic therapies after insulin initiation in patients with type 2 diabetes
Feed Sources
